HRP20201688T1 - Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation - Google Patents

Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation Download PDF

Info

Publication number
HRP20201688T1
HRP20201688T1 HRP20201688TT HRP20201688T HRP20201688T1 HR P20201688 T1 HRP20201688 T1 HR P20201688T1 HR P20201688T T HRP20201688T T HR P20201688TT HR P20201688 T HRP20201688 T HR P20201688T HR P20201688 T1 HRP20201688 T1 HR P20201688T1
Authority
HR
Croatia
Prior art keywords
alpha
sialylation
recombinant fsh
fsh including
pharmaceutical preparation
Prior art date
Application number
HRP20201688TT
Other languages
Croatian (hr)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16194925.0A external-priority patent/EP3144318B1/en
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of HRP20201688T1 publication Critical patent/HRP20201688T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (4)

1. Rekombinantni FSH (rFSH), uključujući α2,3- i α2,6-sialilaciju naznačen time što je od 10% do 20% ukupne sialilacije α2,6-sialilacija.1. Recombinant FSH (rFSH), including α2,3- and α2,6-sialylation characterized in that from 10% to 20% of the total sialylation is α2,6-sialylation. 2. Farmaceutski pripravak, naznačen time što sadrži rekombinantni FSH prema patentnom zahtjevu 1.2. Pharmaceutical preparation, characterized in that it contains recombinant FSH according to patent claim 1. 3. Farmaceutski pripravak prema patentnom zahtjevu 2 naznačen time što nadalje sadrži hCG i/ili LH.3. Pharmaceutical preparation according to patent claim 2 characterized in that it further contains hCG and/or LH. 4. Farmaceutski pripravak prema patentnom zahtjevu 2 ili zahtjevu 3 naznačen time što se koristi u liječenju neplodnosti.4. Pharmaceutical preparation according to patent claim 2 or claim 3, characterized in that it is used in the treatment of infertility.
HRP20201688TT 2008-04-16 2020-10-20 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation HRP20201688T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP16194925.0A EP3144318B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
HRP20201688T1 true HRP20201688T1 (en) 2020-12-25

Family

ID=73835254

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201688TT HRP20201688T1 (en) 2008-04-16 2020-10-20 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Country Status (6)

Country Link
ES (1) ES2833533T3 (en)
HR (1) HRP20201688T1 (en)
HU (1) HUE051918T2 (en)
JO (1) JO3808B1 (en)
LT (1) LT3144318T (en)
SA (1) SA114350153B1 (en)

Also Published As

Publication number Publication date
SA114350153B1 (en) 2016-02-01
ES2833533T3 (en) 2021-06-15
JO3808B1 (en) 2021-01-31
LT3144318T (en) 2021-02-10
HUE051918T2 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
HRP20161520T1 (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
CL2007002214A1 (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
CY1119140T1 (en) COMPOSITION COMPOSITIONS AND METHODS OF CONSTRUCTION AND USE
CL2007002866A1 (en) COMPOUNDS DERIVED FROM 6-SUBSTITUTES-2- (BENCIMIDAZOLIL) PURINA AND PURINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF AUTOIMMUNE DISEASES, INFLAMMATORY DISEASE, DISEASE MEDIATED BY M
ES2721898T3 (en) Stable formulations to lyophilize therapeutic particles
BR112015032338A2 (en) personal care compositions and articles
CL2007003635A1 (en) COMPOUNDS DERIVED FROM 6-AMINO-PURIN-8-ONA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PROCESS TO PREPARE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF ALLERGIC, VIRAL OR CANCER DISEASES.
SV2010003581A (en) 4- (4-CIANO-2-TIOARIL) DIHYDROPIRIMIDINONES AND ITS USE
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
PH12013502192A1 (en) Antibodies against human angiopoietin 2
AR065247A1 (en) NAPADISYLATE AND / OR HEMINAPADISYLATE SALT OF 5- (2 - {[6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXIL] AMINO] -1-HYDROXYYLATE) -8-HYDROXYCHINOLIN-2 (1H) -ONA, COMPOSITIONS PHARMACEUTICS THAT CONTAIN THEM AND USES IN THE TREATMENT OF ASTHMA AND OTHER PULMONARY DISEASES.
PE20151727A1 (en) 2-AZA-BICYCLE ACID [2.2.1] HEPTANE-3-CARBOXYL (BENZYL-CYAN-METHYL) -AMIDES SUBSTITUTED, CATEPSIN C INHIBITORS
MX2009011218A (en) Nucleic acid microparticles for pulmonary delivery.
CL2007002948A1 (en) 2-CHLORINE-5- (3,6-DIHYDRO-3-METHYL-2,6-DIOXO-4- (TRIFLUOROMETIL) -1- (2H)-PYRIMIDINYL) -4-FLUOR-N - ((METIL (1-METHYLETY) AMINO) SULFONILE] BENZAMIDE; PROCESS FOR THE PREPARATION OF SUCH HYDRATION; PHYTO-PROTECTION COMPOSITION; AND METHOD FOR CON
PE20160930A1 (en) THERAPEUTIC POLYMERIC NANOPARTICLES AND METHODS FOR THEIR PREPARATION AND USE.
RS54905B1 (en) Improved recombinant human follicle-stimulating hormone
IL208355A (en) 3,7-dihydropurine-2,6-dione derivatives, processes for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
DOP2011000091A (en) INHALABLE PARTICLES THAT INCLUDE TIOTROPIO
WO2008045564A8 (en) Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
CY1115961T1 (en) ORVEPITANT MALEATE ANHYDRATED FORM OF CRYSTAL MALINE
ATE527878T1 (en) COMPOSITIONS AND METHODS RELATING TO THE EXPRESSION AND BIOLOGICAL ACTIVITY OF BOvine FOLLICLE-STIMULATING HORMONE
EA201390979A1 (en) COMPOSITIONS OF BENZIMIDAZOLES WITH MODIFIED SURVIVAL
CL2008000982A1 (en) COMPOUNDS DERIVED FROM 5-OXO-ISOXAZOL-CARBOXAMIDA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PROCEDURE OF PRODUCTION OF THE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROTIC DISORDERS, OF METABOLISM OF
MA32224B1 (en) (Pyrazolyl-carbonyl) imidazolidinone derivatives for the treatment of retroviral diseases
HRP20201688T1 (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation